A PET/CT clinical trial targeting fibroblast activated protein

A new PET/CT clinical trial targeting fibroblast activated protein in lung cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100045757

Enrollment

Unknown

Registered

2021-04-24

Start date

2020-09-07

Completion date

Unknown

Last updated

2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Gold Standard:Routine 18F-FDG PET

tumor-stromal&#32

protein&#32

FAPI-04&#32

(68Ga-FAPI-04&#32

or&#32

18F-FAPI-04)&#32

PET

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Voluntary signing of informed consent; patients with suspected lung cancer brain metastases; patients who have been diagnosed with lung cancer brain metastases.

Exclusion criteria

Exclusion criteria: Critical emergency patients, respiratory depression, (pulmonary) airway obstruction, or tissue hypoxia; drug and/or alcohol abusers, allergies; those who cannot tolerate and cooperate with the examination; the investigator judges that they are not suitable for participating in this study.

Design outcomes

Primary

Measure	Time frame
Sensitivity and specificity of FAPI-04 PET/CT imaging in the diagnosis of lung cancer with brain metastases;	—

Secondary

Measure	Time frame
Differences in SUVmax and T/NT values between benign and malignant intracranial lesions;	—

Countries

China

Contacts

Public ContactGanghua Tang

Nanfang Hospital, Southern Medical University

gtang0224@126.com+86 15986449188

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 20, 2026